Listed

Cognition Therapeutics Inc

CGTXNasdaqCIK 1455365HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$7.7m, Q2 FY2026
Net income−$3.9m, Q2 FY2026
Cognition Therapeutics Inc, income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m11.7Research and development, Q3 FY2023, three months to 2023-09-30$11.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0001558370-24-015436.Report this figure11.6Research and development, Q4 FY2023, three months to 2023-12-31$11.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-20, accession 0001558370-25-003341. Derived: 12-month figure less the 9-month figure.Report this figure10.6Research and development, Q1 FY2024, three months to 2024-03-31$10.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-07, accession 0001558370-25-006612.Report this figure11.6Research and development, Q2 FY2024, three months to 2024-06-30$11.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001558370-25-010771.Report this figure11.4Research and development, Q3 FY2024, three months to 2024-09-30$11.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure8.2Research and development, Q4 FY2024, three months to 2024-12-31$8.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001104659-26-034880. Derived: 12-month figure less the 9-month figure.Report this figure10.8Research and development, Q1 FY2025, three months to 2025-03-31$10.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure11.5Research and development, Q2 FY2025, three months to 2025-06-30$11.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure3.8Research and development, Q3 FY2025, three months to 2025-09-30$3.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure11.1Research and development, Q4 FY2025, three months to 2025-12-31$11.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001104659-26-034880. Derived: 12-month figure less the 9-month figure.Report this figure6.1Research and development, Q1 FY2026, three months to 2026-03-31$6.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure5.1Research and development, Q2 FY2026, three months to 2026-06-30$5.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure
Operating income$m(14.7)Operating income, Q3 FY2023, three months to 2023-09-30−$14.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015436.Report this figure(15.2)Operating income, Q4 FY2023, three months to 2023-12-31−$15.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-20, accession 0001558370-25-003341. Derived: 12-month figure less the 9-month figure.Report this figure(14.1)Operating income, Q1 FY2024, three months to 2024-03-31−$14.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-07, accession 0001558370-25-006612.Report this figure(14.7)Operating income, Q2 FY2024, three months to 2024-06-30−$14.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001558370-25-010771.Report this figure(14.5)Operating income, Q3 FY2024, three months to 2024-09-30−$14.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure(10.7)Operating income, Q4 FY2024, three months to 2024-12-31−$10.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001104659-26-034880. Derived: 12-month figure less the 9-month figure.Report this figure(13.8)Operating income, Q1 FY2025, three months to 2025-03-31−$13.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure(14.0)Operating income, Q2 FY2025, three months to 2025-06-30−$14.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure(6.4)Operating income, Q3 FY2025, three months to 2025-09-30−$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure(13.7)Operating income, Q4 FY2025, three months to 2025-12-31−$13.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001104659-26-034880. Derived: 12-month figure less the 9-month figure.Report this figure(8.8)Operating income, Q1 FY2026, three months to 2026-03-31−$8.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure(7.7)Operating income, Q2 FY2026, three months to 2026-06-30−$7.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(6.7)Net income, Q3 FY2023, three months to 2023-09-30−$6.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015436.Report this figure(8.1)Net income, Q4 FY2023, three months to 2023-12-31−$8.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-20, accession 0001558370-25-003341. Derived: 12-month figure less the 9-month figure.Report this figure(9.2)Net income, Q1 FY2024, three months to 2024-03-31−$9.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure(7.0)Net income, Q2 FY2024, three months to 2024-06-30−$7.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure(9.9)Net income, Q3 FY2024, three months to 2024-09-30−$9.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure(7.8)Net income, Q4 FY2024, three months to 2024-12-31−$7.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001104659-26-034880. Derived: 12-month figure less the 9-month figure.Report this figure(8.5)Net income, Q1 FY2025, three months to 2025-03-31−$8.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure(6.7)Net income, Q2 FY2025, three months to 2025-06-30−$6.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure(4.9)Net income, Q3 FY2025, three months to 2025-09-30−$4.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure(3.3)Net income, Q4 FY2025, three months to 2025-12-31−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001104659-26-092362. Derived: 12-month figure less the 9-month figure.Report this figure(4.6)Net income, Q1 FY2026, three months to 2026-03-31−$4.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure(3.9)Net income, Q2 FY2026, three months to 2026-06-30−$3.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure
Diluted EPS$ per share(0.22)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001558370-24-015436.Report this figurenot reported(0.27)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-07, accession 0001558370-25-006612.Report this figure(0.18)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001558370-25-010771.Report this figure(0.25)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figurenot reported(0.14)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure(0.11)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure(0.06)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figurenot reported(0.05)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure(0.04)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure
Basic EPS$ per share(0.22)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001558370-24-015436.Report this figurenot reported(0.27)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-07, accession 0001558370-25-006612.Report this figure(0.18)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001558370-25-010771.Report this figure(0.25)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figurenot reported(0.14)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure(0.11)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure(0.06)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figurenot reported(0.05)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure(0.04)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.04 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure

Balance sheet

Cash and equivalents$34.0m, Q2 FY2026
Shareholders' equity$33.0m, Q2 FY2026
Cognition Therapeutics Inc, balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m33.0Cash and equivalents, Q3 FY2023, at 2023-09-30$33.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-02, accession 0001558370-23-017321.Report this figure29.9Cash and equivalents, FY2023, at 2023-12-31$29.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-20, accession 0001558370-25-003341.Report this figure34.7Cash and equivalents, Q1 FY2024, at 2024-03-31$34.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-07, accession 0001558370-24-006911.Report this figure28.5Cash and equivalents, Q2 FY2024, at 2024-06-30$28.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001558370-25-010771.Report this figure22.0Cash and equivalents, Q3 FY2024, at 2024-09-30$22.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure25.0Cash and equivalents, FY2024, at 2024-12-31$25.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-26, accession 0001104659-26-034880.Report this figure16.4Cash and equivalents, Q1 FY2025, at 2025-03-31$16.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-07, accession 0001558370-25-006612.Report this figure10.7Cash and equivalents, Q2 FY2025, at 2025-06-30$10.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure39.3Cash and equivalents, Q3 FY2025, at 2025-09-30$39.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure36.8Cash and equivalents, FY2025, at 2025-12-31$36.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure31.1Cash and equivalents, Q1 FY2026, at 2026-03-31$31.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure34.0Cash and equivalents, Q2 FY2026, at 2026-06-30$34.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure
Current assets$m36.0Current assets, Q3 FY2023, at 2023-09-30$36.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-02, accession 0001558370-23-017321.Report this figure34.2Current assets, FY2023, at 2023-12-31$34.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-20, accession 0001558370-25-003341.Report this figure38.0Current assets, Q1 FY2024, at 2024-03-31$38.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0001558370-24-006911.Report this figure33.6Current assets, Q2 FY2024, at 2024-06-30$33.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001558370-24-011464.Report this figure26.8Current assets, Q3 FY2024, at 2024-09-30$26.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015436.Report this figure29.6Current assets, FY2024, at 2024-12-31$29.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-26, accession 0001104659-26-034880.Report this figure22.9Current assets, Q1 FY2025, at 2025-03-31$22.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-07, accession 0001558370-25-006612.Report this figure19.0Current assets, Q2 FY2025, at 2025-06-30$19.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001558370-25-010771.Report this figure42.9Current assets, Q3 FY2025, at 2025-09-30$42.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure48.0Current assets, FY2025, at 2025-12-31$48.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure35.8Current assets, Q1 FY2026, at 2026-03-31$35.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure38.3Current assets, Q2 FY2026, at 2026-06-30$38.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure
Total assets$m38.8Total assets, Q3 FY2023, at 2023-09-30$38.8m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-02, accession 0001558370-23-017321.Report this figure35.2Total assets, FY2023, at 2023-12-31$35.2m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-20, accession 0001558370-25-003341.Report this figure38.9Total assets, Q1 FY2024, at 2024-03-31$38.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0001558370-24-006911.Report this figure34.4Total assets, Q2 FY2024, at 2024-06-30$34.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001558370-24-011464.Report this figure27.6Total assets, Q3 FY2024, at 2024-09-30$27.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001558370-24-015436.Report this figure30.2Total assets, FY2024, at 2024-12-31$30.2m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-26, accession 0001104659-26-034880.Report this figure23.5Total assets, Q1 FY2025, at 2025-03-31$23.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-07, accession 0001558370-25-006612.Report this figure19.6Total assets, Q2 FY2025, at 2025-06-30$19.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001558370-25-010771.Report this figure43.4Total assets, Q3 FY2025, at 2025-09-30$43.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure48.4Total assets, FY2025, at 2025-12-31$48.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure36.1Total assets, Q1 FY2026, at 2026-03-31$36.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure38.9Total assets, Q2 FY2026, at 2026-06-30$38.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure
Current liabilities$m8.2Current liabilities, Q3 FY2023, at 2023-09-30$8.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-02, accession 0001558370-23-017321.Report this figure10.2Current liabilities, FY2023, at 2023-12-31$10.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-20, accession 0001558370-25-003341.Report this figure9.5Current liabilities, Q1 FY2024, at 2024-03-31$9.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0001558370-24-006911.Report this figure10.9Current liabilities, Q2 FY2024, at 2024-06-30$10.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001558370-24-011464.Report this figure12.7Current liabilities, Q3 FY2024, at 2024-09-30$12.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015436.Report this figure11.1Current liabilities, FY2024, at 2024-12-31$11.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-26, accession 0001104659-26-034880.Report this figure11.0Current liabilities, Q1 FY2025, at 2025-03-31$10.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-07, accession 0001558370-25-006612.Report this figure12.4Current liabilities, Q2 FY2025, at 2025-06-30$12.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001558370-25-010771.Report this figure6.7Current liabilities, Q3 FY2025, at 2025-09-30$6.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure13.9Current liabilities, FY2025, at 2025-12-31$13.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure6.1Current liabilities, Q1 FY2026, at 2026-03-31$6.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure5.5Current liabilities, Q2 FY2026, at 2026-06-30$5.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure
Total liabilities$m9.8Total liabilities, Q3 FY2023, at 2023-09-30$9.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-02, accession 0001558370-23-017321.Report this figure10.7Total liabilities, FY2023, at 2023-12-31$10.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-20, accession 0001558370-25-003341.Report this figure10.0Total liabilities, Q1 FY2024, at 2024-03-31$10.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0001558370-24-006911.Report this figure11.4Total liabilities, Q2 FY2024, at 2024-06-30$11.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001558370-24-011464.Report this figure13.1Total liabilities, Q3 FY2024, at 2024-09-30$13.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001558370-24-015436.Report this figure11.5Total liabilities, FY2024, at 2024-12-31$11.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-26, accession 0001104659-26-034880.Report this figure11.2Total liabilities, Q1 FY2025, at 2025-03-31$11.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-07, accession 0001558370-25-006612.Report this figure12.6Total liabilities, Q2 FY2025, at 2025-06-30$12.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001558370-25-010771.Report this figure6.9Total liabilities, Q3 FY2025, at 2025-09-30$6.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure14.1Total liabilities, FY2025, at 2025-12-31$14.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure6.2Total liabilities, Q1 FY2026, at 2026-03-31$6.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure5.9Total liabilities, Q2 FY2026, at 2026-06-30$5.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure
Shareholders' equity$m28.9Shareholders' equity, Q3 FY2023, at 2023-09-30$28.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001558370-24-015436.Report this figure24.5Shareholders' equity, FY2023, at 2023-12-31$24.5m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-26, accession 0001104659-26-034880.Report this figure28.9Shareholders' equity, Q1 FY2024, at 2024-03-31$28.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure23.0Shareholders' equity, Q2 FY2024, at 2024-06-30$23.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure14.5Shareholders' equity, Q3 FY2024, at 2024-09-30$14.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure18.8Shareholders' equity, FY2024, at 2024-12-31$18.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure12.3Shareholders' equity, Q1 FY2025, at 2025-03-31$12.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure7.0Shareholders' equity, Q2 FY2025, at 2025-06-30$7.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure36.5Shareholders' equity, Q3 FY2025, at 2025-09-30$36.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure34.3Shareholders' equity, FY2025, at 2025-12-31$34.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure29.9Shareholders' equity, Q1 FY2026, at 2026-03-31$29.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure33.0Shareholders' equity, Q2 FY2026, at 2026-06-30$33.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure

Cash flow

Operating cash flow−$3.1m, Q2 FY2026
Capital expenditure$1.0k, Q4 FY2024
Cognition Therapeutics Inc, cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(4,161)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$4.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001558370-24-015436. Derived: 9-month figure less the 6-month figure.Report this figure(5,456)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-20, accession 0001558370-25-003341. Derived: 12-month figure less the 9-month figure.Report this figure(7,244)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$7.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-07, accession 0001558370-25-006612.Report this figure(5,997)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$6.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001558370-25-010771. Derived: 6-month figure less the 3-month figure.Report this figure(6,851)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$6.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107402. Derived: 9-month figure less the 6-month figure.Report this figure(8,382)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$8.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001104659-26-034880. Derived: 12-month figure less the 9-month figure.Report this figure(9,877)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$9.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure(5,623)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0001104659-26-092362. Derived: 6-month figure less the 3-month figure.Report this figure(5,651)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$5.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107402. Derived: 9-month figure less the 6-month figure.Report this figure(3,437)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001104659-26-034880. Derived: 12-month figure less the 9-month figure.Report this figure(5,542)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure(3,053)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$3.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0001104659-26-092362. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k58.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$58.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0001558370-24-015436. Derived: 9-month figure less the 6-month figure.Report this figure30.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$30.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-20, accession 0001558370-25-003341. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107402. Derived: 9-month figure less the 6-month figure.Report this figure1.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001104659-26-034880. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)90.62m, Q2 FY2026
Cognition Therapeutics Inc, shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares23.0Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3023,024,026 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-02, accession 0001558370-23-017321.Report this figure29.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3129,094,592 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0001558370-24-006911.Report this figure29.6Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3029,614,822 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001558370-24-011464.Report this figure30.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3030,365,506 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001558370-24-015436.Report this figure33.7Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3133,735,269 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-07, accession 0001558370-25-006612.Report this figure40.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3040,062,954 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001558370-25-010771.Report this figure40.4Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3040,418,065 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure61.8Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3161,828,149 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure63.7Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3063,690,945 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure78.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3077,951,513 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001104659-25-107402.Report this figure89.2Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3189,191,313 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-08, accession 0001104659-26-057545.Report this figure90.6Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3090,624,381 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure

Shares outstanding: 95.09mShares outstanding, period not labelled, at 2026-08-0495,093,746 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-07, accession 0001104659-26-092362.Report this figure at Aug 4, 2026, from the cover of the 10-Q filed Aug 7, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. Listed shows no prices and gives no investment advice.